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while microcins are active against Gram-negative bacteria. The narrow spectrum of action generally
displayed by bacteriocins from lactic acid bacteria represents an important limitation for the appli-
cation of these peptides as clinical drugs or as food biopreservatives. The present study describes the
design and expression of a novel recombinant hybrid peptide combining enterocin CRL35 and
microcin V named Ent35–MccV. The chimerical bacteriocin displayed antimicrobial activity against
enterohemorrhagic Escherichia coli and Listeria monocytogenes clinical isolates, among other path-
ogenic bacteria. Therefore, Ent35–MccV may ﬁnd important applications in food or pharmaceutical
industries.
 2012 Federation of European Biochemical Societies. Published by Elsevier B.V.1. Introduction common of them is gastroenteritis. Moreover, Shiga toxin-Bacteriocins are ribosomally synthesized bacterial antimicro-
bial peptides [1]. Many food pathogens as well as opportunistic
bacteria that cause food spoilage are inhibited by these peptides.
Particularly, bacteriocins from lactic acid bacteria (LAB) are being
employed as antimicrobial agents for foods. In this regard, nisin
and pediocin PA-1 were approved as food biopreservatives [2].
Actually, nisin was approved as food antimicrobial agent in 1969
by FAO/WHO Expert Committee on Food Additives and its use is
permitted in over 50 countries nowadays. Biopreservation meth-
ods are being developed to respond to the market demand of fresh
and minimally processed foods with longer shelf-life. One of the
critical limitations to the use of LAB bacteriocins as biopreservative
agents is the narrow spectrum of action they display. As a matter of
fact, pediocin PA-1 is inactive against Gram-negative bacteria and
nisin has to be employed in combination with chemical or physical
treatments that disrupt the outer membrane (OM) when used to
inhibit Gram-negative pathogens [3,4]. Pathogenic strains of
Escherichia coli can cause different foodborne illnesses. The mostal Societies. Published by Elsevier
U, colony forming units; IM,
ocin; OM, outer membrane
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A. Bellomio).producing E. coli is a foodborne pathogen causing alarming out-
breaks. A possible alternative to control Gram-negative in foods
is the use of antimicrobial peptides secreted by Gram-negative
bacteria, known as microcins. To this purpose, Pomares et al. devel-
oped a chymotrypsin-susceptible MccJ25 variant, inactivated by
digestive enzymes to be used as food preservative [5]. However,
microcins are only active against Gram-negative bacteria [6]. Sim-
ilar to pediocin-like bacteriocins, microcins belonging to class IIa,
such as microcin V, are linear polypeptides and the removal of
the leader peptide is the unique post-translational modiﬁcation
that they undergo before being secreted by the cells [6–8]. Most
remarkable is the fact that they have a similar mechanism of
action. It was found that many linear bacteriocins can disrupt the
cellular membrane and kill sensitive microorganisms. The expres-
sion of an integral membrane protein that acts as a bacteriocin-
speciﬁc receptor determines the sensitivity of a bacterial strain
to the bacteriocin. The mannose phosphotransferase system acts
as receptor for pediocin-like bacteriocins [9]. Meanwhile, three
different proteins may serve as a speciﬁc receptor for linear
microcins, namely the membrane component F0 of the ATP
synthase, SdaC, and the mannose permease, required by MccH47,
MccV, and MccE492, respectively [10–12]. Because of the Gram-
negative envelope structure, an additional step is required by class
IIa microcins, i.e. an OM transporter system is used for these
peptides to reach the plasma membrane receptor.B.V. Open access under CC BY-NC-ND license.
L. Acuña et al. / FEBS Open Bio 2 (2012) 12–19 13The enterocin CRL35, a pediocin-like bacteriocin isolated from
Argentinean regional cheese, has a potent antilisterial activity
but is inactive against Gram-negative bacteria [13]. On the other
hand, microcin V previously known as colicin V is speciﬁcally
active against Gram-negative bacteria [14]. In order to obtain a
peptide with a broader antimicrobial spectrum the required por-
tions of genes encoding the bacteriocins enterocin CRL35 and
microcin V, namely munA and cvaC, were fused by asymmetrical
PCR. The resulting munA-cvaC chimerical gene was cloned and
expressed in E. coli. The hybrid bacteriocin puriﬁed from E. coli ex-
tracts, named Ent35–MccV, showed inhibitory activity against
enterohemorrhagic E. coli, Listeria monocytogenes, and other patho-
genic Gram-positive and Gram-negative bacteria.
2. Materials and methods
2.1. Bacterial strains and culture conditions
The bacteria and culture conditions used in this work are listed
in Table 1. The strain E. coli DH5a was used as the host for recom-
binant plasmids.
2.2. Genetic manipulations
In this work we fused by polymerase chain reactions (PCR) the
regions of munA and cvaC encoding for the structural portion of
enterocin CRL35 and microcin V, respectively. The procedure isTable 1
Inhibitory spectrum of Ent35–MccV and parental bacteriocins.
Strain Culture conditions, media/temp. Source,
Gram-positive
L. innocua 7 TSB/30 C INRA
L. monocytogenes FBUNT1 TSB/37 C FBQF –
L. monocytogenes FBUNT2 TSB/37 C FBQF –
L. monocytogenes EGDe TSB/37 C ATCC: B
Enterococcus faecalis FBUNT1 TSB/37 C FBQF –
S. aureus FBUNT1 M9/37 C FBQF –
S. aureus FBUNT2 M9/37 C FBQF –
S. epidermidis FBUNT1 M9/37 C FBQF
Acinetobacter baumannii TSB/37 C Malbran
E. mundtii CRL35 TSB/30 C CERELA
Gram-negative
E. coli MC4100 M9/37 C CGSC
E. coli O157:H7 M9/37 C ATCC 70
E. coli (UPEC215) M9/37 C FBQF –
E. coli (UPEC217) M9/37 C FBQF –
E. coli (UPEC219) M9/37 C FBQF –
E. coli (UPEC228) M9/37 C FBQF –
E. coli (UPEC229) M9/37 C FBQF –
E. coli (UPEC230) M9/37 C FBQF –
E. cloacae M9/37 C FBQF –
S. marscecens M9/37 C FBQF –
K. pneumoniae M9/37 C FBQF –
Y. pestis M9/37 C FBQF –
C. freundii M9/37 C FBQF –
P. aeruginosa M9/37 C FBQF –
S. Typhimurium FBUNT1 M9/37 C FBQF –
S. Typhimurium SL3770 M9/37 C SGSC
S. Newport FBUNT1 M9/37 C FBQF –
E. coli MC4100 (pHK11) M9/37 C [15]
E. coli LA1 M9/37 C DsdaC::
E. coli LA2 M9/37 C DcirA::k
E. coli NC1 M9/37 C DtonB::k
INRA, Jouy-en-Josas, France; FBQF: Facultad de Bioquímica, Química y Farmacia; Unive
CERELA: Centro de Referencias para Lactobacillos, Tucumán, Argentina; CGSC: E. coli Gen
Nacional de Laboratorios e Institutos de Salud (ANLIS) Dr. Carlos Malbrán, Argentina; CI
a Symbols represent relative activity by diffusion in agar, evaluated by measuring t
5 mm < da < 10 mm; +++: da > 10 mm.
b Ent35: enterocin CRL35.shown schematically in Fig. 1A. A colony of Enterococcus mundtii
CRL35 as template and the primers munAF3 (forward-50CAT
GCCATGGGTAAATACTACGGTAATGGA) and 3GentR (reverse-50TC
CTCCTCCACTTTTCCAACCAGCTGCTC) [13] were used for amplifying
munA gene. On the other hand, the gene cvaC was ampliﬁed from
the plasmid pHK11 using primers colVF3G (forward-50GGAG GAG
GACTTCAGGGCGTGATATTGC) and colVR (reverse-50GGATCCTTA
TAAACAAACATCACT) [15]. Recognition sites for restriction en-
zymes NcoI in munAF3 and BamHI in colVR and the region encod-
ing for the hinge triglycine in 3GentR and colVF3G are underlined.
The reaction was carried out under standard conditions speciﬁed
by the enzyme supplier (AccuPrime™ Taq DNA Polymerase High
Fidelity, Invitrogen).The PCR program included an initial denatur-
ation step at 94 C for 5 min, followed by 30 cycles (50 C for
30 s, 68 C for 40 s and 94 C for 1 min). At the end of the PCR
program, an elongation step (68 C, 5 min) was included.
Finally, the fusion of munA with cvaC was carried out by an
asymmetric PCR reaction [16]. The PCR products of munA and cvaC
(1 ll each one in a 50 ll reaction) were used as template, munAF3
and colVr as primers at 0.4 lM ﬁnal concentration and the internal
munAR3g primer at 0.4 nM ﬁnal concentration was introduced to
produce the fusion. Nucleotide concentrations and reaction condi-
tions were those recommended by the supplier of the enzyme
GoTaq DNA Polymerase (Promega). The program used was: 94 C
5 min, followed by 10 cycles (94 C 1 min, 55 C 1 min, 72 C
40 s), 20 cycles (94 C 1 min, 40 C 1 min, 72 C 40 s) and
72 C 10 min. The PCR product (shown in Fig. 1B) was puriﬁed fromreference or relevant genotype Inhibitory activitya
Ent35–MccV Ent35b MccV
+++ +++ 
CI +++ +++ 
CI +++ +++ 
AA-679   
CI  +++ 
CI +  
CI +++  
+  
– CI   
[13]   
+++  +++
0728 +++  ++
CI +++  ++
CI +++  ++
CI +++  ++
CI ++  ++
CI +++  +++
CI   
CI +  +
CI +  
CI +  
CI   
CI   
CI   
CI   
  
CI   
  
km – this work   
m – this work   
m – Natalia Corbalán   
rsidad Nacional de Tucumán, Argentina; ATCC: American Type Culture Collection;
etic Stock Center; SGSC: Salmonella Genetic Stock Center; Malbran: Administración
: clinical isolate.
he average diameter (da) of inhibition zones. : no inhibition; +: da < 5 mm; ++:
Fig. 1. munA-cvaC construction. (A) Schematic representation of the PCR strategy used to fuse munA and cvaC. First, each gene was ampliﬁed incorporating an overlapping
fragment which encode for an interpeptide ﬂexible region. In the second PCR, the products of munA and cvaC PCR were used as template and 3GentR (1:1000 dilution with
respect to munAF3 and colVR primers) was used to fuse the two DNAs. (B) Electrophoretic analysis of the product of the asymmetrical PCR in 1% agarose gel stained with
(GelredTM (Biotium). Lane 1: DNA step ladder 100 bp (Invitrogen). Lane 2: asymmetric PCR product. The arrow marks the position of migration of the hybrid product. (C)
Amino acid sequences of enterocin CRL35, MccV and the hybrid Ent35–MccV. The hinge region is in bold.
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gested with NcoI and BamHI and cloned in linearized pET28b(+)
(Novagen). The ligation mixture was used to transform E. coli
DH5a obtaining pMA24. The cloned gene was sequenced and
analyzed for its structure.
E. coli LA1 and LA2 were obtained introducing a kanamycin
resistance cassette by Phage P1 vir transduction from the strains
E. coli JW2767-1 and JW2142-1, respectively [17]. The strain
E. coli NC1 was a generous gift from Natalia Corbalán (INSIBIO,
Tucumán-Argentina).
2.3. Gene expression and bacteriocins puriﬁcation for activity
determinations
Ent35–MccV was expressed from pMA24 in E. coli BL21 [DE3]
(pLysS) grown in LB (Sigma) at 37 C. When the culture reached
an OD 0.6 the Ent35–MccV synthesis was induced with isopropyl
b-thiogalactoside 0.5 mM and temperature was changed to 30 C.After 3 h, cells were collected by centrifugation in 10 mM HEPES,
pH 7, PMSF 0.5 mM (buffer A), lysed using a French press and cen-
trifuged at 47,000xg, 4 C for 1 h. The supernatant was heated
(10 min, 100 C) and centrifuged (10 min, 10,000xg). The resultant
supernatant was then puriﬁed through a C18 cartridge (Supelco)
and eluted with a stepwise buffer A:acetonitrile gradient (0%, 5%,
10%, 20%, 30% and 50% v/v). Ent35–MccV eluted with 50% acetoni-
trile. This fraction was used to test the antimicrobial activity after
solvent removal (Savant SpeedVac System). Protein concentration
was determined using Quant-iT™ Protein Assay Kit (Invitrogen).
The parental bacteriocins, enterocin CRL35 and MccV, were
puriﬁed as previously described [13,18].
2.4. RP-HPLC puriﬁcation of Ent35–MccV and MALDI-TOF MS analysis
The supernatant obtained from the centrifugation of the heated
extract (Section 2.3) was precipitated with ammonium sulfate to a
ﬁnal concentration of 70% (w/v). Proteins were harvested by
L. Acuña et al. / FEBS Open Bio 2 (2012) 12–19 15centrifugation, re-suspendedwith 0.1% (v/v) aqueous triﬂuoroacetic
acid (TFA) and fractionated by Reversed Phase (RP)-HPLC using a
modular system HP 1100 Agilent Technology (Palo Alto, CA, USA)
equipped with a Vydac (Hesperia, CA, USA) C4 column (214TP52,
5 lm, 250  2.1 mm i.d.). After 5 min of isocratic elution at 10% sol-
vent B (0.1% TFA in HPLC-grade acetonitrile, v/v), a 10–70% linear
gradient of B over 60 min was applied at a ﬂow rate of 0.2 ml/min.
Solvent Awas 0.1% TFA inHPLC-gradewater (v/v). For each analysis,
aliquots of approximately 100 ll of heated supernatant were frac-
tionated. Column efﬂuents were monitored by UV detection at 220
and 280 nm. Protein fractions weremanually collected and concen-
trated in a speed-vac for mass spectrometry (MS) analysis. Prior to
MS analysis HPLC fractions were further desalted by C4 Zip Tipmi-
cro-columns (Millipore, Bedford, CA, USA), washing with 0.1% TFA
and eluting with 70% acetonitrile (v/v) containing 0.1% TFA.
Matrix assisted laser desorption ionization-time of ﬂight (MAL-
DI-TOF) MS experiments were carried out on a Voyager DE-Pro
spectrometer (PerSeptive BioSystems, Framingham, MA, USA)
equipped with a N2 laser (k = 337 nm). Sinapinic acid (Sigma), dis-
solved in 50% acetonitrile containing 0.1% TFA at a concentration of
10 mg/ml, was used as the matrix. Puriﬁed HPLC fractions (1 ll)
were mixed with matrix (1 ll) directly on the MALDI target and
air dried. The mass spectra were acquired in the positive linear
ion mode using the Delayed Extraction (DE) technology. The
instrument operated at an accelerating voltage of 20 kV. External
mass calibration was performed with a commercial standard pro-
tein mixture (Sigma), including bovine insulin (average MH+
5734.5), cytochrome c (average MH+ 12362.0) and horse myoglo-
bin (average MH+ 16952.3). Raw data were analyzed using the soft-
ware program Data Explorer 4.0 purchased with the spectrometer.
2.5. Antimicrobial activity and bacterial viability assays
Drops of each puriﬁed peptide (20 ll, 350 lg of protein/ml)
were spotted in a TSB (Difco) or M9 (Sigma) plate. Once the drop-
lets were adsorbed, the plate was covered with 4 ml of 0.6% agar
previously inoculated with 106 cells of the test strain. Incubation
was carried out over night at 30 C or 37 C. Antimicrobial activity
was evaluated by measuring the diameter of the inhibition halos.
The peptide solutions were successively diluted before the drops
were spotted. The antimicrobial activity units (AU/ml) were calcu-
lated as the reciprocal of the highest two-fold dilution showing
growth inhibition halo against Listeria innocua 7 or E. coli MC4100.
For viability determination E. coliMC4100 and L. innocua 7 were
grown to mid-log phase, harvested by centrifugation (10 min,
10000xg), and re-suspended at approximately 1.107 colony form-
ing units per milliliter (CFU/ml) in 50 mM HEPES, pH 7.4,
12.5 mM glucose. The suspensions were treated with the bacterio-
cin (50 AU/ml corresponding to each assayed bacterial strain) and
the CFUs versus time were determined.
2.6. Tricine SDS-PAGE
Electrophoresis gels were prepared as previously described [19]
and the samples were treated with loading buffer without
b-mercaptoethanol. After ﬁxing, the gels were washed successively
with ethanol 70%, 30% and sterile bidistilled water. The gels were
placed on TSB or LB (Sigma) agar plates, covered with 10 ml of
0.6% (w/v) agar inoculated with 106 cells of L. monocytogenes
FBUNT1 or E. coli MC4100. The plates were incubated at 37 C for
16 h and the inhibition zones were examined.
2.7. Nucleotide sequence accession number
The DNA sequence of munA-cvaC was deposited at the EMBL
Nucleotide Sequence Database, EMBL-Bank ID: FR865441.3. Results
3.1. Construction of munA-cvaC
As described in Section 2.2, the hybridmunA-cvaC was obtained
by asymmetrical PCR (see Fig. 1A). First, each gene was ampliﬁed
using the previously described primers. The DNA sequence encod-
ing the hinge region was incorporated with 3GentR (reverse primer
for munA) and colVF3G (forward primer for cvaC) and overlapping
fragments were generated. After that, the two fragments were
fused by an asymmetrical PCR (Fig. 1A) [20]. The hybrid gene
was cloned, expressed in E. coli BL21 [DE3] and puriﬁed by reverse
phase chromatography. The hinge region between two antimicro-
bial peptides was reported to be critical for obtaining active anti-
microbial hybrid peptides [21]; thus, a Gly–Gly–Gly ﬂexible
region was introduced between enterocin CRL35 and MccV. The
amino acid sequence of parental and the hybrid Ent35–MccV are
shown in Fig. 1C.
3.2. Spectrum of action
As shown in Table 1, the antimicrobial spectrum of Ent35–MccV
was assayed against a number of Gram-positive and Gram-
negative bacteria. In agreement with well-established data, none
of the Gram-positive strains tested were inhibited by MccV and
enterocin CRL35 was not active against Gram-negative bacteria.
Similar to the parental bacteriocins, the hybrid peptide displayed
potent antimicrobial activity against Listeria spp. and E. coli.
Ent35–MccV was active against L. innocua 7, two clinical isolated
strains of L. monocytogenes, namely FBUNT1 and FBUNT2, and
was inactive against the enterocin CRL35 natural resistant strain
L. monocytogenes EGDe. All the Gram-negative bacteria inhibited
by MccV were also inhibited by Ent35–MccV. In particular, the
peptide displayed antimicrobial activity against Enterobacter cloa-
cae and E. coli; including the laboratory strain MC4100, the entero-
hemorrhagic E. coli O157:H7 and 5 out of 6 clinical isolates of
uropathogenic strains (UPEC). In fact, only the strain UPEC230
was not affected by Ent35–MccV. However, UPEC230 is a microcin-
ogenic strain that produces an antimicrobial compound which was
characterized by cross-streaking as MccV [22]. It was previously
suggested that a relationship between higher-molecular-mass
microcins, such as MccV and urovirulence may occur [23]. More-
over, Ent35–MccV displayed antimicrobial activity against other
clinical isolates Gram-positive and Gram-negative strains on which
enterocin CRL35 or MccV are inactive, such as Staphylococcus
aureus FBUNT1 and FBUNT2, Staphylococcus epidermidis, Serratia
marscecens FBUNT1 and Klebsiella pneumoniae FBUNT1. The hybrid
peptide was inactive against Enterococcus faecalis FBUNT1,
on which enterocin CRL35 is active. Some bacteria tested
(Acinetobacter baumannii, Yersinia pestis, Citrobacter freundii,
Pseudomonas aeruginosa, Salmonella enterica serovar Typhimurium,
and S. enterica serovar Newport) were resistant.
3.3. Mechanism of action
To explore the mechanism of action of Ent35–MccV, its antimi-
crobial activity was assayed against wild type E. coli MC4100 and
isogenic mutant strains, bearing mutations in the cirA, tonB or sdaC
genes. All the mutant strains are resistant to MccV because CirA
and TonB are necessary to transport the peptide across the OM
[24], and SdaC is the IM receptor [11]. The results showed that
the mutant strains (E. coli LA1, LA2 and NC1) were also resistant
to Ent35–MccV, indicating that the same proteins are required by
the hybrid bacteriocin in order to exert antimicrobial action on
E. coli.
Fig. 2. Effect of Ent35–MccV and parental bacteriocins on the viability of L. innocua 7 and E. coliMC4100 cells. The bacterial suspensions were treated with 50 AU/ml of each
bacteriocin (see Section 2.4). Cell viability is expressed as CFU/ml at different times. (A) L. innocua 7 cells without treatment (s), Ent35–MccV (j), and enterocin CRL35 (D).
(B) E. coli MC4100 control without treatment (s), Ent35–MccV (j), and MccV (D). The results represent the average of three independent experiments.
Fig. 3. RP-HPLC separation of the heated cellular extract. Cellular extract of E. coli
BL21 [DE3] (pMA24) were treated as described in Section 2.4. Chromatogram was
monitored at (A) k = 220 nm and (B) k = 280 nm. Peaks were collected and
individually analyzed by MALDI-TOF MS.
16 L. Acuña et al. / FEBS Open Bio 2 (2012) 12–19The enterocin CRL35 producer and immune bacterial strain,
E. mundtii CRL35, was immune to the hybrid peptide, indicating
that the immunity protein for enterocin CRL35 protects against
Ent35–MccV [13]. Similarly, E. coli MC4100 cells harboring
pHK11, which encodes the MccV immunity protein Cvi [15], were
also immune to Ent35–MccV.
Both, Enterocin CRL35 and MccV are bactericidal [11,25]. To
investigate whether Ent35–MccV is able to kill the target cells,
we studied the time course killing effect on E. coli MC4100 and
L. innocua 7 using the same AU/ml (Fig. 2). Ent35–MccV was able
to decrease the viability of both bacteria. After two hours of treat-
ment with Ent35–MccV the L. innocua 7 viable cells decreased one
order of magnitude compared to the control curve in the absence
of the peptide. A similar result was obtained with enterocin
CRL35 (Fig. 2A). When the experiments were carried out with
E. coli as sensitive strain, cell viability decreased two orders of
magnitude by treatment with Ent35–MccV, meanwhile the same
antimicrobial activity units of MccV decreased only one log, com-
pared to the control without antimicrobial peptide (Fig. 2B). These
results clearly demonstrate the bactericidal ability of Ent35–MccV
against both bacteria.3.4. Ent35–MccV characterization
The MALDI-TOF MS analysis of Ent35–MccV samples prepared
as described in Sections 2.3 and 2.4 showed a single signal at m/z
7271.6. According to previously published MS data [26,27] this
component was tentatively identiﬁed as to the E. coli cold-
shock-C secreted protein.
The missed detection of any further protein component has to
be most likely ascribed to a high ionization efﬁciency of the CSP-
C and to subsequent suppression ion effects. Therefore, the sample
was subjected to preliminary RP-HPLC separation. In Fig. 3A and B
are shown the UV chromatograms at k = 220 and k = 280, respec-
tively. Peaks were manually collected and analyzed by MALDI-
TOF MS. The dominant component with m/z 7271.6 was contained
in the peak no. 1 at retention time (RT) 36.7 min. The MALDI-
TOF peptide mass mapping carried out after tryptic hydrolysis
(not shown) conﬁrmed, through the use of the Protein Prospector
search engine (http://prospector.ucsf.edu), that it is the CSP-C of
E. coli (Uniprot accession: P0A9Y6). Though at a low degree, the
CSP-C also contaminated the later eluting HPLC fractions.
The MALDI-TOF spectrum of the peak no. 5 at RT 46.2 min
(Fig. 4) displayed a signal at m/z 13179.8. The measured MW is
compatible with that expected for Ent35–MccV in which a proteo-
lytic cleavage at the Gly1 has occurred. Interestingly, the
corresponding chromatographic peak resulted clearly increased
by the k = 280 detection (Fig. 3B), if compared to the other peaks.
This was attributed to the presence of as many as 4 Trp residues
in the sequence of Ent35–MccV, that strongly enhanced k = 280
absorbance.
The remaining main signals in the MALDI spectrum can be
assigned to other co-eluting fragments that arise from proteolysis
of Ent35–MccV as schematized in Table 2, thereby supporting the
identiﬁcation of Ent35–MccV. The proteolytic cleavages preferen-
tially involved the carboxy-terminal of speciﬁc Gly residues. No
further polypeptide chains ascribable to fragments of Ent35–MccV
were detected by the MS analysis of the remaining HPLC fractions.
It has to be underlined that the attempt of characterizing Ent35–
MccV by MALDI peptide mass mapping was unsuccessful, most
likely because of both a low degree of trypsinolysis of the chimeric
protein and the occurrence of interfering peptides generated from
E. coli CSP-C.
3.5. Tris-tricine SDS-PAGE and Ent35–MccV assay
Puriﬁed preparations containing Ent35–MccV and the parental
bacteriocins were analyzed by tricine SDS-PAGE. Gels revealed by
Fig. 4. MALDI-TOF MS analysis of the HPLC fraction no. 5. The mass signal 13179.8 is compatible with the expected molecular weight of Ent35–MccV (2–135 chain). The other
signals are assigned in Table 2. The upper panel shows the Ent35–MccV sequence in which the proteolytic cleavage sites are indicated.
Table 2
MALDI-TOF MS assignment of Ent35–MccV proteolytic fragments in the HPLC peak
no. 5.
Measured m/z Expected m/za Assignment Cleavage
13179.8 13202.8 Ent35–MccV (2–135) G1
10932.2 10930.2 Ent35–MccV (23–135) A22
10648.3 10646.8 Ent35–MccV (26–135) I25
9281.3 9276.4 Ent35–MccV (1–98) G98
6605.4 6602.4 Ent35–MccV (71–135) G70
a The expected m/z of the Ent35–MccV fragments were calculated considering
Cys engaged in disulﬁde bonds.
L. Acuña et al. / FEBS Open Bio 2 (2012) 12–19 17biological activity against L. monocytogenes FBUNT1 and E. coli
MC4100 are shown in Fig. 5A and B, respectively. Ent35–MccV
inhibition zones were located at 13.3 kDa (lane 2, band (a) for
both gels), close to the migration band expected for unhydrolyzed
Ent35–MccV (theoretical MW 13259.8 Da). These results demon-
strated that the hybrid peptide is actually responsible for the anti-
microbial activity, different from any small-sized proteolytic
fragment produced during the puriﬁcation. There is an additional
inhibition zone (c), which could be attributed to Ent35–MccV olig-
omers. It was only observed when antimicrobial activity was tested
against E. coli MC4100 SDS-PAGE detection (Fig. 5B).
4. Discussion
In this paper, a new hybrid bacteriocin between the pediocin-
like bacteriocin, enterocin CRL35 and the linear microcin, MccV is
reported. Johnsen et al. reported the fusion of N- and C-terminal
portions of various ‘‘pediocin-like’’ bacteriocins and found that
the C-terminal half of the peptide determines the spectrum of ac-
tion against species and strains of Gram-positive bacteria [28,29].
Moreover, a 15-mer peptide that spans pediocin PA-1 from the
center toward the C-terminal portion inhibited its biological activ-
ity. Thus, the receptor binding region could be localized within the
C-terminal portion of these bacteriocins [30]. The N-terminal re-
gion must be involved in the membrane perturbation induced by
the peptide, since a 15-mer peptide derived from enterocinCRL35 produced an enhancement of enterocin CRL35 antimicrobial
activity and showed antimicrobial activity [31,32]. On the other
hand, Azpiroz and Laviña constructed hybrid microcins fusing the
N- and C-terminal domains of MccV and MccH47. They arrived
to the conclusion that the C-terminal domains of these class II
microcins are involved in the recognition of the OM receptor for
the target cell uptake and the N-terminal domain is the toxic re-
gion of the molecule [33]. Both, class IIa of LAB bacteriocin and
class II of microcins must have an IM receptor binding region.
The antimicrobial spectrum displayed by Ent35–MccV demon-
strates that both bacteriocins are active in the chimerical peptide.
Ent35–MccVmust have two receptor binding regions, two toxic re-
gions and the OM receptor binding domain in the MccV portion.
Although the hybrid bacteriocin appears to have a similar mecha-
nism of action than the parental bacteriocins and is recognized by
the two immunity proteins, i.e. MunC and Cvi, the antimicrobial
activity of the hybrid does not correspond exactly to the sum of
the antimicrobial activities of the parental peptides. The toxic do-
mains belonging to both peptides might be active simultaneously
once Ent35–MccV binds to the plasma membrane receptor in
E. coli cells. This fact could explain the better capacity to kill
E. coli cells than MccV and the better performance killing E. coli
than L. innocua cells. There is a persistence of L. innocua 7 and
E. coli MC4100 populations larger than 1.106 CFU/ml and
1.105 CFU/ml after treatment with the hybrid antimicrobial pep-
tide. Vignolo et al. observed that population of L. monocytogenes
decreased initially after enterocin CRL35 treatment and increased
upon further incubation [34]. Another microcins and bacteriocins
have similar kinetics of cell destruction [35,36]. Although more
experiments testing the antimicrobial activity of Ent35–MccV in
foods or complex ﬂuid matrices (whole blood, plasma or serum)
must be performed, in order to ﬁnd the right conditions in which
the spontaneous emergence and outgrowth of a bacteriocin-
resistant bacterial population can be avoided. In fact, we strongly
believe that Ent35–MccV could be employed in combination with
other bacteriocins or other chemical or physical food treatments
[4,34,37].
The antimicrobial activity displayed by the hybrid against bac-
terial strains which are not inhibited by the parental bacteriocins
Fig. 5. Bacteriocins analyzed by Tris-Tricine SDS-PAGE and revealed by biological activity. Lane 1 contained the prestained molecular mass marker – see Blue Plus2,
Invitrogen (both gels). (A) Gel revealed by biological activity against L. monocytogenes FBUNT1 showing the zones of growth inhibition by the bacteriocin bands (a) and (b).
Lanes: 2, Ent35–MccV; 3, enterocin CRL35 (MM: 4289.8 Da). (B) Gel revealed using E. coliMC4100 as indicator strain. Lanes: 2, Ent35–MccV (band a); 3, MccV, MM: 8735.7 Da
(band b).
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ules in Ent35–MccV. It is possible that a membrane protein of
the target cells serves as a receptor for one of the parental bacteri-
ocins or Ent35–MccV. However, a steric barrier or an inappropriate
bacteriocin position could impede the interaction between the
toxic domain and the cellular membrane. Therefore, the parental
bacteriocins could not act causing the disruption of the cell mem-
brane. After receptor binding, the hybrid peptide could have
increased possibilities for a favorable toxic domain-membrane
interaction. These results must be thoroughly investigated in fu-
ture research in order to gain more insight into the mechanism
of action of membrane active bacteriocins.
Ent35–MccV is active against the emergent foodborne patho-
gens, the Gram-negative enterohemorrhagic E. coli O157:H7 and
the Gram-positive L. monocytogenes. More broad spectra hybrid
bacteriocins could be obtained based on the idea proposed in this
work. Furthermore, chimerical bacteriocin–microcin peptides
must be useful to study the mechanism of action of bacteriocins
and for applications in medicine, veterinary or food industry.
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